Home › Cases › NSTEMI Management in Chronic Kidney Disease
NSTEMI
NSTEMI Management in Chronic Kidney Disease
6 questions
Question 1 · AKI risk in NSTEMI
Correct answer: CKD increases risk of contrast-induced AKI, bleeding risk (antiplatelet + uremia), and drug dose adjustments needed for renally-cleared medications
Why
NSTEMI + CKD: increased risk of contrast-induced nephropathy (CIN) — prophylaxis with IV hydration pre/post. Uremia impairs platelet function → bleeding risk with DAPT. Renally-cleared drugs need dose adjustment (LMWH, fondaparinux, novel anticoagulants). For DOACs, use Cockcroft–Gault CrCl, not eGFR: dabigatran is contraindicated below30mL/min; factor-Xa inhibitors have drug/indication-specific restrictions and dose reductions. Adjust LMWH for renal function; avoid NSAIDs.
Key point
NSTEMI + CKD: AKI risk from contrast, bleeding from uremia, drug dose adjustments. Hydrate before/after angiography.
Question 2 · Contrast-induced AKI prevention
Correct answer: IV 0.9% saline 1 ml/kg/hour (e.g. 3–4 hours before and 4–6 hours after); adjust for fluid overload or urgent angiography. Minimise contrast volume; use low/iso-osmolar contrast
Why
Contrast-associated AKI prevention: use IV 0.9% saline 1ml/kg/hour, e.g. 3–4h before and 4–6h after when IV prophylaxis is indicated; avoid fluid overload and do not delay urgent angiography to complete prehydration. Minimise contrast volume; use low/iso-osmolar contrast. Avoid NSAIDs. Consider holding ACEi/ARB if eGFR <30, rather than routinely at 32. NAC is not recommended; statins do not provide consistent contrast-AKI protection, but remain indicated after NSTEMI.
Key point
Contrast AKI prevention: risk-based IV saline, minimum contrast and no NAC. Avoid NSAIDs; do not routinely stop ACEi/ARB at eGFR 32 or delay urgent angiography.
Question 3 · LMWH dosing in CKD
Correct answer: Fondaparinux 2.5mg SC daily is suitable. If enoxaparin is chosen, CrCl 32 does not itself require dose reduction; monitor bleeding
Why
Fondaparinux 2.5mg SC daily is a NICE option when immediate angiography is not planned; avoid at CrCl<20ml/min. It is renally cleared. For NSTEMI, enoxaparin 1mg/kg SC BD at CrCl 32; 1mg/kg SC OD for CrCl 15–30, with careful monitoring. Severe/unstable renal impairment: discuss UFH, titrated using clotting tests; it is easier to adjust/reverse, not wholly free of renal clearance.
Key point
NSTEMI, no immediate angiography: fondaparinux 2.5mg SC OD if suitable (avoid CrCl <20). Enoxaparin: 1mg/kg SC BD at CrCl 32; 1mg/kg SC OD at CrCl 15–30. Monitor bleeding; severe/unstable renal impairment → discuss titrated UFH.
Question 4 · DAPT in CKD
Correct answer: DAPT still indicated. Aspirin + P2Y12 inhibitor (ticagrelor or prasugrel). Bleeding risk higher but cardiac benefit maintained. More careful monitoring needed
Why
CKD increases bleeding risk through platelet dysfunction but is not a reason to withhold indicated DAPT. Ticagrelor is metabolised mainly by CYP3A4 and needs no renal dose adjustment. Prasugrel: in NSTEMI, use only after coronary anatomy is known and PCI is intended; weigh bleeding risk. Choose the P2Y12 agent with the ACS team, considering PCI and any oral anticoagulation. Aspirin 75 mg daily is maintenance therapy, not a CKD-specific dose reduction.
Key point
CKD does not prohibit DAPT. Maintain aspirin 75 mg daily; choose P2Y12 therapy by PCI plan, bleeding risk and oral anticoagulation. Ticagrelor needs no renal dose adjustment.
Question 5 · Statins in CKD with NSTEMI
Correct answer: Atorvastatin for cardiovascular protection: NICE CKD starting dose 20 mg daily, increasing if the lipid target is unmet. CKD is not a contraindication. Monitor LFTs; check CK if muscle symptoms
Why
CKD is not a statin contraindication. NICE recommends atorvastatin 20 mg daily, increasing (e.g. 40–80 mg) if the lipid target is unmet and eGFR ≥30; agree higher doses with a renal specialist below 30. Benefit is cardiovascular; prevention of kidney failure is not established. Simvastatin + gemfibrozil is contraindicated because of myopathy risk, irrespective of CKD. Atorvastatin itself needs no renal dose adjustment.
Key point
CKD: atorvastatin 20 mg daily, titrate to lipid response; renal specialist for higher doses if eGFR <30. Cardiovascular benefit. Avoid simvastatin + gemfibrozil.
Question 6 · ACEi in CKD post-NSTEMI
Correct answer: Yes — start low-dose ramipril and check U&E in 1–2 weeks. A stable 10–15% fall from baseline is acceptable; investigate a fall ≥25% or rising K+
Why
Start low-dose ramipril when stable: cardiac benefit after MI; CKD alone is not a contraindication.
- U&E/BP: baseline, 1–2 weeks after starting and dose increases; earlier if renal risk warrants.
- Stable 10–15% eGFR fall: usually continue/recheck. Fall ≥25% or creatinine rise ≥30%: check dehydration/NSAIDs; reduce or stop if no reversible cause.
- K+ ≥6.0 mmol/L: stop ramipril and seek urgent hyperkalaemia review; check other potassium-raising drugs. Review rising K+ before this threshold; do not routinely start if baseline K+ >5.0.
Renal protection is especially relevant in albuminuric CKD.
Key point
Ramipril + U&E in 1–2 weeks. Stable 10–15% eGFR fall can be acceptable; ≥25% needs investigation. K+ ≥6.0: stop ramipril; urgent review.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.